Mirae Asset Global ETFs Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.04M	Buy	169,721 +96,605	+132%	+$1.83M	﹤0.01%	1056
2026 Q1	$1.58M	Buy	73,116 +2,975	+4%	+$57.6K	﹤0.01%	1287
2025 Q4	$1.51M	Buy	70,141 +26,933	+62%	+$568K	﹤0.01%	1297
2025 Q3	$829K	Buy	43,208 +758	+2%	+$13.5K	﹤0.01%	1600
2025 Q2	$726K	Buy	42,450 +13,621	+47%	+$581K	﹤0.01%	1606
2025 Q1	$1.87M	Sell	28,829 -1,403	-5%	-$148K	﹤0.01%	1178
2024 Q4	$3.67M	Sell	30,232 -814	-3%	-$99.8K	0.01%	866
2024 Q3	$3.88M	Sell	31,046 -5,825	-16%	-$805K	0.01%	846
2024 Q2	$5.83M	Buy	+36,871	New	+$4.74M	0.01%	701

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's SRPT Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Sarepta Therapeutics (SRPT) stake by 132% in Q2 2026, buying an estimated $1.83M and bringing the position to 169,721 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

Mirae Asset Global ETFs Holdings first reported a position in SRPT in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.83M in Q2 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Mirae Asset Global ETFs Holdings held 169,721 shares of Sarepta Therapeutics worth $3.04M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 96,605 Sarepta Therapeutics shares in Q2 2026, an estimated $1.83M.
Sarepta Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1056 holding.
Mirae Asset Global ETFs Holdings first reported a position in Sarepta Therapeutics in Q2 2024 and has held it in 9 quarters since.
Mirae Asset Global ETFs Holdings's Sarepta Therapeutics position peaked at $5.83M in Q2 2024.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.